Aas A T, Brun A, Pero R W, Salford L G
Department of Neurosurgery, Lund University Hospital, Sweden.
Br J Neurosurg. 1994;8(2):187-92. doi: 10.3109/02688699409027965.
Modern cancer therapy has improved the prognosis for several tumour types. This, however, does not apply to the largest group of brain tumours, the malignant astrocytomas grades III-IV. Hence, there is need for new ideas to improve treatment. Ca2+ and the Ca(2+)-binding protein calmodulin have been shown to be involved in the processes conferring stability to DNA in proliferating neoplastic cells. We have combined the calmodulin-inhibiting neuroleptic drug chlorpromazine (CPZ), with the anti-neoplastic drug 1,3-bis(2-chloroethyl-1)-nitrosourea (BCNU) in a treatment regime for rats with glioma cells implanted in the brain. A highly significant inhibiting effect upon the tumour growth was noticed, not by CPZ or BCNU as single drugs, but with their combination.
现代癌症治疗已经改善了几种肿瘤类型的预后。然而，这并不适用于最大的脑肿瘤群体，即III-IV级恶性星形细胞瘤。因此，需要新的思路来改善治疗。已表明Ca2+和Ca(2+)结合蛋白钙调蛋白参与了在增殖的肿瘤细胞中赋予DNA稳定性的过程。我们将钙调蛋白抑制性抗精神病药物氯丙嗪（CPZ）与抗肿瘤药物1,3-双（2-氯乙基-1）-亚硝基脲（BCNU）联合用于植入脑胶质瘤细胞的大鼠的治疗方案中。结果发现，对肿瘤生长有高度显著的抑制作用，不是CPZ或BCNU单独作为药物时，而是它们联合使用时。
